研究单位:[1]Betta Pharmaceuticals Co., Ltd.[2]Cancer Institute and Hospital, Chinese Academy of Medical Sciences [3]People's Liberation Army 307 Hospital[4]Tongji Hospital
研究目的:
This randomised, multi-center, controlled trial is designed to assess the efficacy and safety of icotinib with concurrent radiotherapy versus chemotherapy with concurrent radiotherapy in non-small cell lung cancer